Endothelial NOS, estrogen receptor β, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The identification of biomarkers that distinguish between aggressive and indolent forms of prostate cancer (PCa) is crucial for diagnosis and treatment. In this study, we used cultured cells derived from prostate tissue from patients with PCa to define a molecular mechanism underlying the most aggressive form of PCa that involves the functional activation of eNOS and HIFs in association with estrogen receptor beta (ERbeta). Cells from patients with poor prognosis exhibited a constitutively hypoxic phenotype and increased NO production. Upon estrogen treatment, formation of ERbeta/eNOS, ERbeta/HIF-1alpha, or ERbeta/HIF-2alpha combinatorial complexes led to chromatin remodeling and transcriptional induction of prognostic genes. Tissue microarray analysis, using an independent cohort of patients, established a hierarchical predictive power for these proteins, with expression of eNOS plus ERbeta and nuclear eNOS plus HIF-2alpha being the most relevant indicators of adverse clinical outcome. Genetic or pharmacologic modulation of eNOS expression and activity resulted in reciprocal conversion of the transcriptional signature in cells from patients with bad or good outcome, respectively, highlighting the relevance of eNOS in PCa progression. Our work has considerable clinical relevance, since it may enable the earlier diagnosis of aggressive PCa through routine biopsy assessment of eNOS, ERbeta, and HIF-2alpha expression. Furthermore, proposing eNOS as a therapeutic target fosters innovative therapies for PCa with NO inhibitors, which are employed in preclinical trials in non-oncological diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676
Carroll, J. S., Liu, X. S., Brodsky, A. S., Li, W., Meyer, C. A., Szary, A. J., Eeckhoute, J., Shao, W., Hestermann, E. V., Geistlinger, T. R., et al. (2005) · Cell · doi:10.1016/j.cell.2005.05.008 · Cited by 1,384
Jiang, B. H., Semenza, G. L., Bauer, C., & Marti, H. H. (1996) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1996.271.4.c1172 · Cited by 1,213
Hypoxia-Inducible Factors, Stem Cells, and Cancer
Keith, B., & Simon, M. C. (2007) · Cell · doi:10.1016/j.cell.2007.04.019 · Cited by 1,179
A role for estrogen receptor β in the regulation of growth of the ventral prostate
Weihua, Z., Mäkelä, S., Andersson, L. C., Salmi, S., Saji, S., Webster, J. I., Jensen, E. V., Nilsson, S., Warner, M., & Gustafsson, J.-Å. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111150898 · Cited by 440
Thomas, D. D., Espey, M. G., Ridnour, L. A., Hofseth, L. J., Mancardi, D., Harris, C. C., & Wink, D. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400453101 · Cited by 289
Cited by
Eltzschig, H. K., & Carmeliet, P. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0910283 · Cited by 2,061
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
“…Oropharynx SCC Aebersold et al. (2001) Ovariana Birner et al. (2001b) Ovarian, serous Daponte et al. (2008) Pancreatic Sun et al. (2007) Prostatee Nanni et al. (2009) Rectal Rasheed et al. (2009) Abbreviations: ER, estrogen receptor; GIST, gastrointestinal stromal tumor; LN, lymph node; NSCLC,…”
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
HIF-1: upstream and downstream of cancer metabolism
Semenza, G. L. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.10.009 · Cited by 1,372
Mak, P., Leav, I., Pursell, B., Bae, D., Yang, X., Taglienti, C. A., Gouvin, L. M., Sharma, V. M., & Mercurio, A. M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.02.030 · Cited by 372
Mimeault, M., & Batra, S. K. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12004 · Cited by 330
Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer
Wesolowski, R., Markowitz, J., & Carson, W. E. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-10 · Cited by 291
HIF1A Overexpression Is Associated with Poor Prognosis in a Cohort of 731 Colorectal Cancers
Baba, Y., Nosho, K., Shima, K., Irahara, N., Chan, A. T., Meyerhardt, J. A., Chung, D. C., Giovannucci, E. L., Fuchs, C. S., & Ogino, S. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090972 · Cited by 285
A study of free radical chemistry: their role and pathophysiological significance.
Gutowski, M., & Kowalczyk, S. (2013) · Acta Biochimica Polonica · doi:10.18388/abp.2013_1944 · Cited by 182
“…in cardiovascular disease (Levy et al., 2009; Strijdom et al., 2009; Rudolph & Freeman, 2009), acute inflammation (Tilg & Moschen, 2008), cancer (Nanni et al., 2009; Parkins et al., 1995), neurodegenerative diseases (Knott & Bossy-Wetzel, 2009; Zhu et al., 2007), and diabetes (Szabo, 2009;…”
BackgroundAugsten, M., Sjöberg, E., Frings, O., Vorrink, S. U., Frijhoff, J., Olsson, E., Borg, Å., & Östman, A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2740 · Cited by 164
Moreno Roig, E., Yaromina, A., Houben, R., Groot, A. J., Dubois, L., & Vooijs, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00224 · Cited by 60
Arginase 2 and nitric oxide synthase: Pathways associated with the pathogenesis of thyroid tumors
Sousa, M. S. A., Latini, F. R. M., Monteiro, H. P., & Cerutti, J. M. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.06.006 · Cited by 39
“Although early findings suggested that elevated iNOS expression levels in a variety of epithelial carcinomas are associated with tumor progression [12,30], the role of eNOS in tumor promotion and maintenance has been recently reported in vivo and in vitro [9,30,31].”
Background
Metadata
- Authors
- Nanni, S., Benvenuti, V., Grasselli, A., Priolo, C., Aiello, A., Mattiussi, S., Colussi, C., Lirangi, V., Illi, B., D’Eletto, M., Cianciulli, A. M., Gallucci, M., De Carli, P., Sentinelli, S., Mottolese, M., Carlini, P., Strigari, L., Finn, S., Mueller, E., Arcangeli, G., Gaetano, C., Capogrossi, M. C., Donnorso, R. P., Bacchetti, S., Sacchi, A., Pontecorvi, A., Loda, M., & Farsetti, A.
- Venue
- Journal of Clinical Investigation
- Published
- 2009-05-01
- Volume
- 119
- Issue
- 5
- Pages
- 1093-1108
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1969423347
- Cited by
- 115
- References
- 6
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.